Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.

Fleisher AS, Munsie LM, Perahia DGS, Andersen SW, Higgins IA, Hauck PM, Lo AC, Sims JR, Brys M, Mintun M, PERISCOPE-ALZ Site Investigators

Open source

DOI: 10.1212/wnl.0000000000208061
Published: 2024 Mar 12
Container: Neurology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1212/wnl.0000000000208061,
  title = {Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.},
  author = {Fleisher AS and Munsie LM and Perahia DGS and Andersen SW and Higgins IA and Hauck PM and Lo AC and Sims JR and Brys M and Mintun M and PERISCOPE-ALZ Site Investigators},
  year = {2024},
  journal = {Neurology},
  doi = {10.1212/wnl.0000000000208061},
  url = {https://doi.org/10.1212/wnl.0000000000208061}
}

RIS

TY  - JOUR
TI  - Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
AU  - Fleisher AS
AU  - Munsie LM
AU  - Perahia DGS
AU  - Andersen SW
AU  - Higgins IA
AU  - Hauck PM
AU  - Lo AC
AU  - Sims JR
AU  - Brys M
AU  - Mintun M
AU  - PERISCOPE-ALZ Site Investigators
PY  - 2024
JO  - Neurology
DO  - 10.1212/wnl.0000000000208061
UR  - https://doi.org/10.1212/wnl.0000000000208061
ER  -

APA

AS, F., LM, M., DGS, P., SW, A., IA, H., PM, H., AC, L., JR, S., M, B., M, M., & Investigators, P. S. (2024). Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.. Neurology. https://doi.org/10.1212/wnl.0000000000208061

Source records

pubmed · retrieved 2026-11-10T21:08:59.241Z